Stroke

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 2, 2022.

Milvexian at doses of 25 mg to 100 mg twice daily showed an approximate 30% relative risk reduction of ischemic stroke compared with placebo.

In a subanalysis of individuals with acute ischemic stroke with tandem lesions, treatment with the Penumbra system resulted in successful revascularization in almost 90% of patients.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Parkinson disease and movement disorders.

For patients with MCA M2 occlusions, use of the Zoom Stroke Solution resulted in significant decreases in National Institutes of Health Stroke Scale scores and no reported perforations or other reperfusion–catheter-related complications.

Neurology News Network for the week ending August 27, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 26, 2022.

Treatment with remote ischemic conditioning performed twice daily for 2 weeks as an adjunct to guideline-based treatment resulted in higher odds of modified Rankin Scale scores between 0 and 1, and 0 and 2.

In a multiday ascending dose trial, pharmacokinetic analysis indicated a direct linear relationship between drug dosing concentration and blood plasma levels for each of the 5 days of dosing.

After adjusting for stroke severity, prestroke physical activity still accounted for a 52% lowered risk for long-term morality following intracerebral hemorrhage and 48% after ischemic stroke.

Here's some of what is coming soon to NeurologyLive® this week.

Patients who received tirofiban did not differ from placebo in terms of 90-day outcomes, and they showed an increased incidence of symptomatic intracranial hemorrhage.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.

Neurology News Network for the week ending August 20, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 19, 2022.

Mendelian randomization analyses identified a significant association between genetically determined chronic kidney disease and intracerebral hemorrhage risk, supporting a causal association between the 2 conditions.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is multiple sclerosis.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 12, 2022.

When combing all 26 studies irrespective of methods, the lowest age-specific divergence in incidence was seen in 3 Southern European studies, and the most pronounced divergence in North American studies.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromyelitis optica spectrum disorder.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 5, 2022.

The Alnylam Pharmaceuticals agent, already approved for the treatment of polyneuropathy in those with hATTR amyloidosis, has now shown promise as a therapeutic option for patients with ATTR amyloidosis with cardiomyopathy.